Results 141 to 150 of about 235,538 (306)

Maximizing Efficacy of Cancer Nanovaccines and Immune Cells Landscape in Responders and Non‐Responders to Immunotherapy

open access: yesAdvanced Science, EarlyView.
To maximize the efficacy of cancer vaccines, adjuvants, collection, lysis, purification, oxidation, loading sites, and sizes, etc., are investigated. The optimized cancer nanovaccines loading whole tumor antigens can cure all or most tumor‐bearing mice in multiple mouse cancer models.
Xiangxiang Xu   +13 more
wiley   +1 more source

Red Blood Cell‐Induced Bacterial Margination Improves Microbial Hemoadsorption on Engineered Cell‐Depleted Thrombi, Restoring Severe Bacteremia in Rats

open access: yesAdvanced Science, EarlyView.
A highly efficient extracorporeal device for treating bacteremia is developed by integrating microfluidic bacterial margination and engineered cell‐depleted thrombi strategically constructed in the device. The rodent models, severely infected with antibiotic‐resistant bacteria, recover from bacteremia after two subsequent extracorporeal blood ...
Bong Hwan Jang   +4 more
wiley   +1 more source

Platelet count may predict abnormal bleeding time among pregnant women with hypertension and preeclampsia [PDF]

open access: bronze, 2001
R. J. McDonagh   +4 more
openalex   +1 more source

Comparative Analysis of Clinical Outcomes and Financial Aspects of Phototherapies and Immunotherapy for Cancer

open access: yesAdvanced Science, EarlyView.
This review compares clinical outcomes, translational progress, and global funding trends across cancer phototherapies—photodynamic, photothermal, and photoimmunotherapy—and conventional immunotherapy. It highlights differences in treatment efficacy, clinical trial status, financial investment, and regulatory challenges, providing a comprehensive ...
Deepak S. Chauhan   +6 more
wiley   +1 more source

Preliminary report: effects of interleukin-1 on platelet counts

open access: hybrid, 1990
Anand Shanker Tewari   +2 more
openalex   +1 more source

Irisin Attenuates Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension via Ubiquitin‐Mediated Regulation of ENO1

open access: yesAdvanced Science, EarlyView.
Irisin is a crucial plasma biomarker and promising therapeutic target that reflects disease severity, pulmonary vascular remodeling status and clinical outcome in patients with pulmonary arterial hypertension (PAH). As a novel protective factor, irisin is downregulated in PAH. By ubiquitination, irisin promotes Enolase 1 degradation and suppresses cell
Na Sun   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy